AU2003268155A1 - Methods of inhibiting tgf beta with substituted pyrazoles - Google Patents

Methods of inhibiting tgf beta with substituted pyrazoles

Info

Publication number
AU2003268155A1
AU2003268155A1 AU2003268155A AU2003268155A AU2003268155A1 AU 2003268155 A1 AU2003268155 A1 AU 2003268155A1 AU 2003268155 A AU2003268155 A AU 2003268155A AU 2003268155 A AU2003268155 A AU 2003268155A AU 2003268155 A1 AU2003268155 A1 AU 2003268155A1
Authority
AU
Australia
Prior art keywords
methods
tgf beta
substituted pyrazoles
inhibiting tgf
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003268155A
Inventor
Jason Scott Sawyer
Beverly Ann Teicher
Jonathan Michael Yingling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2003268155A1 publication Critical patent/AU2003268155A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003268155A 2002-09-19 2003-09-16 Methods of inhibiting tgf beta with substituted pyrazoles Abandoned AU2003268155A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41209802P 2002-09-19 2002-09-19
US60/412,098 2002-09-19
PCT/US2003/026296 WO2004026302A1 (en) 2002-09-19 2003-09-16 Methods of inhibiting tgf beta with substituted pyrazoles

Publications (1)

Publication Number Publication Date
AU2003268155A1 true AU2003268155A1 (en) 2004-04-08

Family

ID=32030805

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003268155A Abandoned AU2003268155A1 (en) 2002-09-19 2003-09-16 Methods of inhibiting tgf beta with substituted pyrazoles

Country Status (2)

Country Link
AU (1) AU2003268155A1 (en)
WO (1) WO2004026302A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004000234A1 (en) * 2003-02-12 2005-04-15 Biogen Idec Inc DERIVATIVE COMPOUNDS 3- (PIRIDIN-2-IL) -4-HETEROARIL-PIRAZOL SUBSTITUTED, ANTAGONISTS OF AIK5 AND / OR AIK4; PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND IN THE TREATMENT OF FIBROTIC DISORDERS AS SCLERODERMIA, LUPUS NEFRITICO, CICATRIZACION DE HERID
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US8642034B2 (en) 2006-10-03 2014-02-04 Genzyme Corporation Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
BR112014009789A2 (en) 2011-10-26 2017-04-25 Seattle Children's Res Inst cysteamine in the treatment of fibrotic disease
WO2016160881A1 (en) 2015-04-01 2016-10-06 Rigel Pharmaceuticals, Inc. TGF-β INHIBITORS
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
TW202028195A (en) * 2018-10-18 2020-08-01 大陸商南京聖和藥業股份有限公司 Compound as TGF-[beta] R1 inhibitor and application thereof
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
MX2022005843A (en) 2019-11-28 2022-07-19 Agomab Spain S L U Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5.
KR20230069169A (en) * 2020-09-17 2023-05-18 얀센 파마슈티카 엔.브이. casein kinase 1 delta modulator
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1246A (en) * 1997-05-22 2004-02-07 Searle & Co Substituted pyrazoles as p38 Kinase inhibitors.

Also Published As

Publication number Publication date
WO2004026302A1 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
PL377778A1 (en) Pyrazole derivatives
AU2003224111A1 (en) Substituted pyrazolo-pyrimidine-4-ones
AU2003292429A8 (en) Pyrazole compounds
AU2003284976A1 (en) Expandable sheath tubing
AU2003296586A1 (en) Pyridazinone derivatives as cdk2-inhibitors
EP1537102A4 (en) Inhibition of phsphoinostide 3-dinase beta
AU2003225580A1 (en) Tricyclic pyrazole derivatives for the treatment of inflammation
AU2003218153A1 (en) Improved thermography catheter
PL375979A1 (en) Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2003072535A8 (en) Substituted hydroxyethylamines
AU2003245984A1 (en) Hetero-cyclicaly substituted imidazotriazines
AU2003264019A1 (en) Metrology hardware adaptation with universal library
AU2003268155A1 (en) Methods of inhibiting tgf beta with substituted pyrazoles
AU2003283626A1 (en) Catheter
AU2003301968A1 (en) 4-aminomethyl-1-aryl-cyclohexylamine derivatives
AU2003243000A1 (en) Tape feeder
AU2003240668A1 (en) Attenuation of metapneumovirus
AU2003273885A1 (en) Morpholine-bridged indazole derivatives
AU2003296564A1 (en) 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives
AU2002353510A1 (en) Nebuliser
AU2003212366A1 (en) Substituted 4-aminocyclohexanols
AU2003234131A1 (en) 5-o-mycaminosyltylonide derivatives
AU2003220483A1 (en) Substituted pyrazolyl compounds for the treatment of inflammation
AU2003267722A1 (en) Imidazol-1-ylmethyl pyridazine derivatives
AU2003244140A1 (en) Catheter

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase